Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice.
The use of genetically modified cells to deliver growth factors has been proposed as a possible treatment for neurodegeneration, including Parkinson's disease. Here we demonstrate that the implantation of fibroblasts genetically modified to secrete fibroblast growth factor-1 (FGF) increased striatal dopamine concentrations in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson's disease.
McLay
R N
RN
Tulane University School of Medicine and New Orleans V.A. Medical Center, New Orleans, LA 70152, USA. james.zadina@tulane.edu
Freeman
S M
SM
Zadina
J E
JE